Solorank
Cached score snapshot
US.WAT · Waters Corporation
110分制 56.1/110；5D動能v2 22/50；排序分 78.1/160
Score breakdown
觀望
Score and price trend
Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.
Move the mouse over the chart lines to inspect readings.
- Main score
- 5D momentum v2
- Candlestick
- Historical projection
- Score turn
- Setup grade
| Model | Median | P25/P75 | 歷史相似情境上漲比例 | Down5 | Actual / compare |
|---|---|---|---|---|---|
| Rolling calibration best | +0.39% | -1.55% / +3.31% | 60% | 7.5% | Actual outcome pending · 0 / 3 bars observed |
| 30D observation | -3.26% | -8.15% / +3.02% | 37.5% | 42.5% | Actual outcome pending · 0 / 30 bars observed |
| Historical projection 10D n=160 | +0.81% | -1.14% / +3.03% | 61.3% | 3.1% | Actual outcome pending · 0 / 10 bars observed |
歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。
2026-08-04 → 2026-12-08 · 120 archived points · 8 Deteriorating signal
Summary
score_with_momentum_v2 = main score + 5D momentum v2
Ranking score
78.1
Display grade
觀望
Model version
cursor_18_27_news_v2_160
Main score
56.1/110 (觀望)
5D momentum v2
22/50 (中)
Score with momentum v2
78.1/160 (低排序)
Risk level
Medium
Rolling setup rating
Setup quality, historical edge, and risk are combined into a rolling S/A/B/C/D/F grade for this snapshot date.
Score turn monitor
Has the score quality changed?
Run more market refreshes to build enough archived points for a turn check.
Signals
技術信號 20.9 · 資金流 14 · 5D動能v2 22
INSTITUTIONAL_DATA_OPTIONAL: Institutional ownership unavailable; neutral money-flow treatment used. FMP_INSTITUTIONAL_FAILED: FMP HTTP 402
Audit trace
Full calculation detail
Calculation detail · 8 sections
Market inputs
Bar count
60
ma20
440.6455
ma50
426.2274
close
468.55
prevClose
455.98
avgVolume20
898632
volumeRatio
0.89
changePercent
2.76
Metrics snapshot
close
468.55
volume
797335
changePercent
2.76
110-point main rating
基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10
Main score
56.1/110
Main rating
觀望
5D momentum v2
22/50
Score with momentum v2
78.1/160
Formula
score_with_momentum_v2 = main_score + momentum_5d_v2_score
基本面 — 2.1/5 · 較差
Dimension score
2.1/5
Dimension grade
較差
Sub-items
pbPoints
0.4
pePoints
0.2
epsPoints
0
roePoints
0
debtPoints
0.5
marginPoints
0
turnoverUsdM
373.5913
volumePoints
0.5
revenuePoints
0
dividendPoints
0
marketCapPoints
0.5
資金流 — 14/20 · 良好
Dimension score
14/20
Dimension grade
良好
Sub-items
cmfPoints
1.6
mfiPoints
2.4
obvPoints
4
vwapPoints
4
institutional
score
2
details
source
optional-neutral
warning
code
INSTITUTIONAL_DATA_OPTIONAL
symbol
US.WAT
message
Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional
true
holderCount
n/a
holderPoints
2
top10ShareRatio
n/a
concentrationPenalty
0
institutionPoints
2
市場環境 — 6.4/15 · 較差
Dimension score
6.4/15
Dimension grade
較差
Sub-items
vix
score
1.8
details
source
twelvedata+fred
vixClose
18.39
trend
score
1.8
details
qqq
ma20
733.184
ma50
725.2622
name
QQQ
close
721.24
points
0.4
spy
ma20
770.4115
ma50
767.5288
name
SPY
close
769.66
points
1.4
source
twelvedata+fred
atrPct
3.0338
atrPoints
2
cciPoints
0.8
vixPoints
1.8
marketTrendPoints
1.8
催化劑 — 2/20 · 較差
Dimension score
2/20
Dimension grade
較差
Sub-items
catalyst
score
2
details
source
finnhub_news_keyword_model
articleCount
4
catalystCount
0
catalystPoints
2
風險管理 — 6.7/10 · 一般
Dimension score
6.7/10
Dimension grade
一般
Sub-items
position
score
1.3
details
atrPct
3.0338
turnoverUsdM
373.5913
liquidityPoints
0.6
volatilityPoints
0.7
rrPoints
1.6
stopLevels
symbol
US.WAT
rr_range
1:1.0-1:2.5
risk_profile
中等
stop_loss_price
440.1206
strength_details
ma_score
1.5
atr_score
1
rsi_score
3
macd_score
3
volume_score
1
market_adjustment
1
risk_reward_ratio
1.5
stop_loss_percent
6.1
take_profit_price
510.2464
target_multiplier
2.2
technical_strength
2
take_profit_percent
8.9
positionPoints
1.3
stopLossPoints
1.8
diversification
score
2
details
method
sector concentration proxy; no portfolio holdings used
sector
Health Care
concentratedSectorPenalty
0
riskRewardRatio
1.4668
stopLossPercent
6.0675
diversificationPoints
2
技術信號 — 20.9/30 · 一般
Dimension score
20.9/30
Dimension grade
一般
Sub-items
bbPoints
3
adxPoints
3
sarPoints
2.4
vcpPoints
1.4
macdPoints
4
vcpPayload
vcp_pass
false
vcp_score
1.4
vcp_reason
站上MA50；升放量(近10日4日)；收盤突破20日高位；Ready=N；Confirm=Y
vcp_metrics
up_days
5
vol_ref
863680
down_days
4
vcp_ready
false
above_ma50
true
avg_vol_10
916110
avg_vol_20
890045
avg_vol_30
863680
range_pct_10
0.0908
range_pct_20
0.0934
range_pct_30
0.1141
up_expand_ok
true
lookback_used
59
near_20d_high
true
contraction_ok
false
down_shrink_ok
false
up_expand_days
4
breakout_20d_ok
true
vol_ratio_10_30
1.0607
dist_to_20d_high
-0.0069
down_shrink_days
1
breakout_level_20d
465.36
vcp_breakout_confirm
true
contraction_ratio_10_30
0.7954
vcp_name_en
Volatility Contraction Pattern
vcp_name_zh
波動收縮形態
vol_contraction
false
kdjAdxPoints
0.7
rsiKdjPoints
3.2
volumeWeight
2
maCrossPoints
1.6
shortRsiPoints
0.4
shortMacdPoints
0.4
volConfirmPoints
0
volumePointsTechnical
0.8
情緒分析 — 4/10 · 較差
Dimension score
4/10
Dimension grade
較差
Sub-items
sentiment
score
4
details
source
finnhub_news_keyword_model
articleCount
4
negativeHits
0
positiveHits
1
sentimentScoreRaw
0.6
sentimentData
raw
{"id":143205210,"url":"https://finnhub.io/api/news?id=75ab2cb990a4fbedefee386c5c7a3d8ef379e14f75addf0dabc7fa52c3d45ecc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"The past six months have been a windfall for Waters Corporation’s shareholders. The company’s stock price has jumped 51.7%, hitting $454.91 per share. This performance may have investors wondering how to approach the situation.","category":"company","datetime":1793053367,"headline":"2 Reasons to like WAT and 1 to stay skeptical"}, {"id":143043366,"url":"https://finnhub.io/api/news?id=99fa4d3e0bda26f1959fe16517cc76281572675f289f75fc28627765efbf6b56","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Waters Corporation has logged a powerful run in recent years, and the stock now sits at a level where investors naturally ask whether the current price is in line with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the question is how that cash flow based estimate stacks up against a share price that has already moved a long way. Over the past 3 years Waters has returned 77.7%, which puts real weight on getting the cash flow valuation call...","category":"company","datetime":1792557067,"headline":"Waters (WAT) Stock Looks 26% Overvalued On Cash Flow Estimates"}, {"id":142730063,"url":"https://finnhub.io/api/news?id=b4ec400d9af121f4582219f4a15c82ddddc99f351205421252b72488151aa5e5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.","category":"company","datetime":1791465000,"headline":"Here's Why You Should Retain WAT Stock in Your Portfolio for Now"}, {"id":142450773,"url":"https://finnhub.io/api/news?id=e4f3fa1f1f92e08c17a14dfe916ac75d46bf808ad6edbd94d849eff1cb26fabd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"In mid-September 2026, Everlywell announced a partnership with Waters Corporation to support at-home HPV cervical cancer screening, while Waters also launched the BD FACSDiscover A7 Cell Analyzer globally, expanding access to advanced flow cytometry for research labs. Together, these moves highlight Waters’ growing role in connected diagnostics and high-parameter cell analysis, deepening its presence across clinical and research workflows. Next, we’ll examine how the expanded at-home HPV...","category":"company","datetime":1790550614,"headline":"The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push"}
raw_source
{"id":143238397,"url":"https://finnhub.io/api/news?id=123b58ad24fb079a3b83666a65de7d0245153a3ccc25616bf707bddfad20d273","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.","category":"company","datetime":1793115060,"headline":"Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests"}, {"id":143205210,"url":"https://finnhub.io/api/news?id=75ab2cb990a4fbedefee386c5c7a3d8ef379e14f75addf0dabc7fa52c3d45ecc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"The past six months have been a windfall for Waters Corporation’s shareholders. The company’s stock price has jumped 51.7%, hitting $454.91 per share. This performance may have investors wondering how to approach the situation.","category":"company","datetime":1793053367,"headline":"2 Reasons to like WAT and 1 to stay skeptical"}, {"id":143202820,"url":"https://finnhub.io/api/news?id=dedac7e55ea3388ab12b0603e5f7af2043af8bf6cf9681e120f8b78c8a4ec212","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 31.5% over the past six months while the S&P 500 was up 6.8%.","category":"company","datetime":1793039447,"headline":"1 healthcare stock for long-term investors and 2 we ignore"}, {"id":143201015,"url":"https://finnhub.io/api/news?id=57e35b2bd284eb30a47293b8018e99be671d9e323f6d25cb064a537adbbe968a","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268513467/image_2268513467.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WAT","summary":"The First Eagle U.S. Fund reported a 4.36% return for Q3 2026, outperforming the S&P 500. Read the full analysis for more details.","category":"company","datetime":1793017800,"headline":"First Eagle U.S. Value Fund Q3 2026 Portfolio Review"}, {"id":143137585,"url":"https://finnhub.io/api/news?id=1f7fc2368699870e1efc10f9dac10e71ba897dfb55efe711f4aac5b4ccafcac7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening. The partnership focuses on at-home sample collection that can be processed through Quest Diagnostics laboratories using the Onclarity HPV assay. The two companies aim to widen access to clinically appropriate cervical cancer testing for patients who face barriers to in clinic screening. The Onclarity Self-Collection Kit...","category":"company","datetime":1792797122,"headline":"Quest Diagnostics (DGX) Backs At Home Cervical Cancer Screening"}, {"id":143132441,"url":"https://finnhub.io/api/news?id=9a6fb933e9b47bcf88a1bfbd04036b06b866bce5ba0cce7b0a846ec75f841f01","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026.","category":"company","datetime":1792756800,"headline":"Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026"}, {"id":143134634,"url":"https://finnhub.io/api/news?id=7e3bae8566dd0681484fe4ae49e9584b49998f9e0e75af3901b87b18ecc89c48","image":"","source":"Benzinga","related":"WAT","summary":"Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center,","category":"company","datetime":1792742783,"headline":"Waters And Labcorp To Expand Access To BD Onclarity HPV Assay"}, {"id":143087262,"url":"https://finnhub.io/api/news?id=eba9a293516889b9db11cf3881c5665bd9e741fb9e36f87cf455c1d1c54b430a","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"WAT","summary":"S&P 500 premarket movers on Oct. 21: SMCI, DELL, VRT, LITE, BE and HPE led gainers, while ISRG, NFLX, T, ABT and DHR led declines.","category":"company","datetime":1792586166,"headline":"S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines"}, {"id":143043366,"url":"https://finnhub.io/api/news?id=99fa4d3e0bda26f1959fe16517cc76281572675f289f75fc28627765efbf6b56","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Waters Corporation has logged a powerful run in recent years, and the stock now sits at a level where investors naturally ask whether the current price is in line with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the question is how that cash flow based estimate stacks up against a share price that has already moved a long way. Over the past 3 years Waters has returned 77.7%, which puts real weight on getting the cash flow valuation call...","category":"company","datetime":1792557067,"headline":"Waters (WAT) Stock Looks 26% Overvalued On Cash Flow Estimates"}, {"id":143028934,"url":"https://finnhub.io/api/news?id=42fb19fac55354e2499a0acbf2bc8308b27df6ce408c5e6156e04c9f73a7e9cc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.","category":"company","datetime":1792502400,"headline":"Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows"}, {"id":143029805,"url":"https://finnhub.io/api/news?id=c270824aac8c817fd6f7f9381a53d4b6e8bb0a1c505153a9ab7ccc2ea7dd14ee","image":"https://image.cnbcfm.com/api/v1/image/108438094-17925143591792514357-49123421093-1080pnbcnews.jpg?v=1792514359&w=1920&h=1080","source":"CNBC","related":"WAT","summary":"Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's \"Halftime Report\" to spotlight Waters Corporation and Thermo Fisher in his \"Best Stocks in the Market.\"","category":"company","datetime":1792500356,"headline":"Josh Brown's \"Best Stocks in the Market:\" Waters and Thermo Fisher"}, {"id":143023828,"url":"https://finnhub.io/api/news?id=f54cdd1ff502cc03ae8cc6fa900a19470b9424c6f9b04dad5cc253b2ff8355f1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a collaboration intended to broaden access to clinically appropriate at-home cervical cancer screening through the FDA-cleared Onclarity™ Self-Collection Kit.1,2,13","category":"company","datetime":1792497600,"headline":"Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option"}, {"id":143010668,"url":"https://finnhub.io/api/news?id=9682767f5944a8ea16d51193bbbb60c91179082a7ddd93cf47f710e54a272e0e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Waters Corporation is all geared up to release its third-quarter earnings next month, and analysts anticipate a double-digit boost in its profitability.","category":"company","datetime":1792416569,"headline":"Earnings Preview: What to Expect From Waters Corporation’s Report"}, {"id":142997770,"url":"https://finnhub.io/api/news?id=ab33f6812a39173b4bbf8ed1420620525807eec66531b4c62963c1ee560e41ed","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"LONDON, October 19, 2026--IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company using its High Definition Immunology™ platform to better understand the immune system and drive a shift in how we understand, diagnose, and treat disease, has today announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood samples collected from UK Biobank participants.","category":"company","datetime":1792393680,"headline":"IMU and UK Biobank to generate the world’s most detailed, large-scale picture of the human immune system for advancing research into health and disease"}, {"id":142997771,"url":"https://finnhub.io/api/news?id=808170f23fc379497c6b8a60ecfb66493710c5f63b2904675d23968f8632c6b4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Ultima Genomics, Inc., developer of ultra-high-throughput next-generation sequencing (NGS) platforms, today announced that its recently launched UG200 Sequencing Platform has been selected to power a new large-scale immune profiling study with IMU Biosciences and UK Biobank. The study will generate one of the most detailed pictures of the human immune system assembled to date, adding a high-resolution immune data layer and a foundational dataset for AI to UK Biobank, one of the world's most impo","category":"company","datetime":1792393500,"headline":"Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation"}, {"id":142945309,"url":"https://finnhub.io/api/news?id=5040160360ff4c52ef340a2bb9f579c9f01e9f273c2f8bb5c296d5105ee48fa6","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"WAT","summary":"Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.71% on an annualized basis producing an average annual return of 11.7%. Currently, Waters has a market capitalization of $42.17 billion. \nBuying","category":"company","datetime":1792082731,"headline":"Here’s How Much You Would Have Made Owning Waters Stock In The Last 20 Years"}, {"id":142966507,"url":"https://finnhub.io/api/news?id=2d2d13366651733cb1b6145af866a2a92742630d55dba52d18f49e1906822cb7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.","category":"company","datetime":1791892800,"headline":"Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release"}, {"id":142883797,"url":"https://finnhub.io/api/news?id=c3d7953d6a5d896f03542e49db2c603dc931f592f1870598f157171386a6fa0b","image":"","source":"Benzinga","related":"WAT","summary":"TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Buy and raises the price target from $475 to $515.","category":"company","datetime":1791892541,"headline":"TD Cowen Maintains Buy on Waters, Raises Price Target to $515"}, {"id":142730063,"url":"https://finnhub.io/api/news?id=b4ec400d9af121f4582219f4a15c82ddddc99f351205421252b72488151aa5e5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.","category":"company","datetime":1791465000,"headline":"Here's Why You Should Retain WAT Stock in Your Portfolio for Now"}, {"id":142728490,"url":"https://finnhub.io/api/news?id=6c2f069d7813e573b0ce8d7ac211fac811097d76de78e6fe7f5c54ae9933a351","image":"","source":"Benzinga","related":"WAT","summary":"Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $460 to $500.","category":"company","datetime":1791373046,"headline":"Barclays Maintains Overweight on Waters, Raises Price Target to $500"}, {"id":142695692,"url":"https://finnhub.io/api/news?id=85c2474c0ddb084841e4c085e22b2a859b346cac22eac3c0e8722cd9d7ee988a","image":"https://cdn.benzinga.com/files/images/story/2026/10/07/SP-500-Set-To-Surge-Like-Never-Before-Be.jpg?width=2048&height=1536","source":"Benzinga","related":"WAT","summary":"Micron, Sandisk and Nvidia lead seven S&P 500 stocks that more than doubled quarterly revenue. Six sell AI hardware.","category":"company","datetime":1791367570,"headline":"Nvidia, Micron and Other 5 S&P 500 Stocks With +100% Revenue Growth"}, {"id":142694485,"url":"https://finnhub.io/api/news?id=205ddd44ff6f1452e358342025e56e33cb0dfa365f5e2fbc16991e2a8a53e86d","image":"https://cdn.benzinga.com/files/images/story/2026/10/06/Golden-Bull-Figurine-In-Foreground-With-.jpg?width=2048&height=1536","source":"Benzinga","related":"WAT","summary":"The S&P 500 hit a record high Tuesday, but only 15 of its 504 stocks did too. The median member trades 25% below its own peak.","category":"company","datetime":1791300578,"headline":"The S&P 500 Is Partying at Record Highs: Only 3% of Its Stocks Were Invited"}, {"id":142662145,"url":"https://finnhub.io/api/news?id=39eb1cdfec2b24808a3835bbdbb63f47c6b13870f9b4d20c113dec5d245a3d8e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Under the framework, the two organisations will initially focus on flow cytometry-based programmes.","category":"company","datetime":1791282532,"headline":"CellCarta, Waters Corporation collaborate on companion diagnostics"}, {"id":142635380,"url":"https://finnhub.io/api/news?id=628d8c80b6c2955b506f4753f539d2fb80521c012b22fa288d5d3c6b9ca77bc3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic partnership with Waters Corporation, a global leader in life sciences and diagnostics, creating a framework to jointly pursue companion diagnostic (CDx) and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies.","category":"company","datetime":1791206100,"headline":"CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development"}, {"id":142633835,"url":"https://finnhub.io/api/news?id=2eb8408fc2372f0d7df88dbbc9133e3a1155d872cc69ffa7774a7678864fa389","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2276411485/image_2276411485.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WAT","summary":"First Trust Water ETF keeps underperforming the broader market, implying that there's more to consider than just demand. I rate the FIW ETF as Sell. Click to read my analysis.","category":"company","datetime":1791185457,"headline":"FIW: Massive Water Infrastructure Needs Aren't Enough To Justify A Buy"}, {"id":142557975,"url":"https://finnhub.io/api/news?id=7c585765141d5585e6d79175cfa3839c39250530199bd4ad81048f0ffa47e24e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 1, 2026, at midnight Eastern Time.","category":"company","datetime":1790859600,"headline":"Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call"}, {"id":142559165,"url":"https://finnhub.io/api/news?id=a369a81d6c981559e667e1d316ee895227cc3414ab79c9d2d8a1f5fca1c4fcd3","image":"","source":"Benzinga","related":"WAT","summary":"Guggenheim analyst Subbu Nambi maintains Waters (NYSE:WAT) with a Buy and raises the price target from $440 to $490.","category":"company","datetime":1790848043,"headline":"Guggenheim Maintains Buy on Waters, Raises Price Target to $490"}, {"id":142559166,"url":"https://finnhub.io/api/news?id=54a96966f4bee0ee2424358170e80a4b6330876c9576d750f0ffe11ba9fb481c","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"WAT","summary":"Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.95% on an annualized basis producing an average annual return of 11.99%. Currently, Waters has a market capitalization of $43.33 billion. \nBuying","category":"company","datetime":1790795749,"headline":"If You Invested $1000 In Waters Stock 20 Years Ago, You Would Have This Much Today"}, {"id":142513513,"url":"https://finnhub.io/api/news?id=4ce869aadf41f489c7b7dafd967ff0fd20e41fe2914cacf122b79c047b5490c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.","category":"company","datetime":1790762713,"headline":"1 Volatile Stock with Promising Prospects and 2 We Avoid"}, {"id":142450773,"url":"https://finnhub.io/api/news?id=e4f3fa1f1f92e08c17a14dfe916ac75d46bf808ad6edbd94d849eff1cb26fabd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WAT","summary":"In mid-September 2026, Everlywell announced a partnership with Waters Corporation to support at-home HPV cervical cancer screening, while Waters also launched the BD FACSDiscover A7 Cell Analyzer globally, expanding access to advanced flow cytometry for research labs. Together, these moves highlight Waters’ growing role in connected diagnostics and high-parameter cell analysis, deepening its presence across clinical and research workflows. Next, we’ll examine how the expanded at-home HPV...","category":"company","datetime":1790550614,"headline":"The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push"}
data_source
finnhub_news_keyword_model
article_count
4
negative_hits
0
positive_hits
1
recomputed_at_score
true
sentiment_score_raw
0.6
source_article_count
30
discarded_article_count
26
sentimentPoints
4
Dimension contribution
Dimension
Raw
Max
Norm %
Contrib
基本面
2.1
5/110
42%
2.1
資金流
14
20/110
70%
14
市場環境
6.4
15/110
42.67%
6.4
催化劑
2
20/110
10%
2
風險管理
6.7
10/110
67%
6.7
技術信號
20.9
30/110
69.67%
20.9
情緒分析
4
10/110
40%
4
5D momentum v2 breakdown
Cursor_18.25 5D momentum v2 0-50
5D momentum v2
22/50
ret_5d
0.0581
max_score
50
max_total
50
raw_total
22
vcp_bonus
0
vol_ratio
0.8958
ret_points
8
vol_points
0
range_ratio
1.2947
volat_points
2
day_range_pct
0.0395
model_version
cursor_18_27_news_v2_160
available_bars
30
breakout_points
8
partial_history
false
pullback_points
0
breakout_vol_bonus
0
first_breakout_20d
true
return_window_days
5
first_breakout_bonus
2
breakout_quality_points
2
Risk management
level
Medium
reason
risk management score >= 6.5/10
position
score
1.3
details
atrPct
3.0338
turnoverUsdM
373.5913
liquidityPoints
0.6
volatilityPoints
0.7
rrPoints
1.6
stopLevels
symbol
US.WAT
rr_range
1:1.0-1:2.5
risk_profile
中等
stop_loss_price
440.1206
strength_details
ma_score
1.5
atr_score
1
rsi_score
3
macd_score
3
volume_score
1
market_adjustment
1
risk_reward_ratio
1.5
stop_loss_percent
6.1
take_profit_price
510.2464
target_multiplier
2.2
technical_strength
2
take_profit_percent
8.9
positionPoints
1.3
stopLossPoints
1.8
diversification
score
2
details
method
sector concentration proxy; no portfolio holdings used
sector
Health Care
concentratedSectorPenalty
0
riskRewardRatio
1.4668
stopLossPercent
6.0675
diversificationPoints
2
Calculation audit log
基本面分析總分: 2.1/5分 資金流分析總分: 14/20分 市場環境分析總分: 6.4/15分 催化劑分析: 2/20分 風險管理總分: 6.7/10分 技術信號分析總分: 20.9/30分 情緒分析: 4/10分 共振率(僅顯示不加分): 0%
Technical indicators
adx
value
92.86
atr
atr
14.2147
rule
ATR / current price; lower volatility scores higher
score
4
atr_pct
3.03
cci
rule
Cursor_18.24 CCI bands
level
超買或超賣風險
score
2
value
187.52
cmf
rule
Cursor_18.24 CMF bands
level
平衡
score
4
value
0.0579
kdj
d
71.73
j
97.23
k
80.23
rule
Cursor_18.24 K/D cross
score
4
signal
金叉
mfi
rule
Cursor_18.24 MFI bands
level
平衡
score
6
value
59.95
obv
rule
Cursor_18.24 recent_slope vs previous_slope
score
10
trend
強流入
value
5336835
recentSlope
89803.5
previousSlope
-325970
rsi
value
69.65
sar
rule
Cursor_18.24 Parabolic SAR
score
8
trend
上升
value
431.988
position
SAR喺價下
distancePct
7.8
previousTrend
上升
ma50
value
426.2274
macd
macd
9.3206
trend
強烈看漲
signal
7.1029
histogram
2.2177
vwap
rule
Cursor_18.24 VWAP 20D consecutive close
score
10
value
440.5471
position
連續5日>VWAP
consecutiveAbove
10
volume
rule
Cursor_18.24 volume ratio
level
無力
ratio
0.89
score
4
avgVolume
898632
currentVolume
797335
derived
ma20
440.6455
ma50
426.2274
prevClose
455.98
avgVolume10
889164
avgVolume20
898632
changePercent
2.76
avgVolumeForScore
898632
ma_cross
ma20
440.6455
ma50
426.2274
rule
Cursor_18.24 MA20/MA50 cross
cross
多頭
score
4
prevMa20
439.381
prevMa50
425.0112
spreadPct
3.38
isVolumeBreakout
false
bollinger
lower
417.5366
upper
463.7544
position
上半部
rsi_short
value
90.93
macd_short
macd
0
trend
中性
signal
0
histogram
0
volume_ratio
ratio
0.89
Raw calculation JSON
{
"risk": {
"level": "Medium",
"reason": "risk management score >= 6.5/10",
"position": {
"score": 1.3,
"details": {
"atrPct": 3.0337638039433106,
"turnoverUsdM": 373.59130627665,
"liquidityPoints": 0.6,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.6,
"stopLevels": {
"symbol": "US.WAT",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 440.1206,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 3,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1.5,
"stop_loss_percent": 6.1,
"take_profit_price": 510.2464,
"target_multiplier": 2.2,
"technical_strength": 2,
"take_profit_percent": 8.9
},
"positionPoints": 1.3,
"stopLossPoints": 1.8,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.4668248049554333,
"stopLossPercent": 6.067527607886621,
"diversificationPoints": 2
},
"total": {
"max": 160,
"result": 78.1,
"formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
"baseScore": 56.1,
"modelVersion": "cursor_18_27_news_v2_160",
"momentum5dScore": 22
},
"market": {
"ma20": 440.6455,
"ma50": 426.2274,
"close": 468.55,
"prevClose": 455.98,
"avgVolume20": 898632,
"volumeRatio": 0.89,
"changePercent": 2.76
},
"sources": {
"catalyst": "finnhub_news_keyword_model",
"sentiment": "finnhub_news_keyword_model",
"fundamentals": "fmp_stable",
"institutional": null,
"marketContext": "twelvedata+fred"
},
"barCount": 60,
"momentum": {
"max": 50,
"result": 22,
"details": {
"ret_5d": 0.05808098046837329,
"max_score": 50,
"max_total": 50,
"raw_total": 22,
"vcp_bonus": 0,
"vol_ratio": 0.895836727356482,
"ret_points": 8,
"vol_points": 0,
"range_ratio": 1.2947406776565251,
"volat_points": 2,
"day_range_pct": 0.03949634061458404,
"model_version": "cursor_18_27_news_v2_160",
"available_bars": 30,
"breakout_points": 8,
"partial_history": false,
"pullback_points": 0,
"breakout_vol_bonus": 0,
"first_breakout_20d": true,
"return_window_days": 5,
"first_breakout_bonus": 2,
"breakout_quality_points": 2
},
"formula": "Cursor_18.25 5D momentum v2 0-50",
"modelVersion": "cursor_18_27_news_v2_160"
},
"scoreMax": 110,
"composite": {
"max": 160,
"result": 78.1,
"formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
"weights": [
{
"raw": 2.1,
"label": "基本面",
"weight": "5/110",
"normalized": 42,
"contribution": 2.1
},
{
"raw": 14,
"label": "資金流",
"weight": "20/110",
"normalized": 70,
"contribution": 14
},
{
"raw": 6.4,
"label": "市場環境",
"weight": "15/110",
"normalized": 42.67,
"contribution": 6.4
},
{
"raw": 2,
"label": "催化劑",
"weight": "20/110",
"normalized": 10,
"contribution": 2
},
{
"raw": 6.7,
"label": "風險管理",
"weight": "10/110",
"normalized": 67,
"contribution": 6.7
},
{
"raw": 20.9,
"label": "技術信號",
"weight": "30/110",
"normalized": 69.67,
"contribution": 20.9
},
{
"raw": 4,
"label": "情緒分析",
"weight": "10/110",
"normalized": 40,
"contribution": 4
}
],
"modelVersion": "cursor_18_27_news_v2_160"
},
"momentumMax": 50,
"scoreStatus": "checked",
"standard110": {
"rating": "觀望",
"result": 56.1,
"details": [
"基本面分析總分: 2.1/5分",
"資金流分析總分: 14/20分",
"市場環境分析總分: 6.4/15分",
"催化劑分析: 2/20分",
"風險管理總分: 6.7/10分",
"技術信號分析總分: 20.9/30分",
"情緒分析: 4/10分",
"共振率(僅顯示不加分): 0%"
],
"formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
"dimensionScores": {
"催化劑": 2,
"基本面": 2.1,
"資金流": 14,
"市場環境": 6.4,
"情緒分析": 4,
"技術信號": 20.9,
"風險管理": 6.7
},
"dimensionDetails": {
"催化劑": {
"max": 20,
"grade": "較差",
"items": {
"catalyst": {
"score": 2,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 4,
"catalystCount": 0
}
},
"catalystPoints": 2
}
},
"基本面": {
"max": 5,
"grade": "較差",
"items": {
"pbPoints": 0.4,
"pePoints": 0.2,
"epsPoints": 0,
"roePoints": 0,
"debtPoints": 0.5,
"marginPoints": 0,
"turnoverUsdM": 373.59130627665,
"volumePoints": 0.5,
"revenuePoints": 0,
"dividendPoints": 0,
"marketCapPoints": 0.5
},
"source": "fmp_stable"
},
"資金流": {
"max": 20,
"grade": "良好",
"items": {
"cmfPoints": 1.6,
"mfiPoints": 2.4,
"obvPoints": 4,
"vwapPoints": 4,
"institutional": {
"score": 2,
"details": {
"source": "optional-neutral",
"warning": {
"code": "INSTITUTIONAL_DATA_OPTIONAL",
"symbol": "US.WAT",
"message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
},
"optional": true,
"holderCount": null,
"holderPoints": 2,
"top10ShareRatio": null,
"concentrationPenalty": 0
}
},
"institutionPoints": 2
}
},
"市場環境": {
"max": 15,
"grade": "較差",
"items": {
"vix": {
"score": 1.8,
"details": {
"source": "twelvedata+fred",
"vixClose": 18.39
}
},
"trend": {
"score": 1.7999999999999998,
"details": {
"qqq": {
"ma20": 733.18400235,
"ma50": 725.2621992000002,
"name": "QQQ",
"close": 721.23999,
"points": 0.4
},
"spy": {
"ma20": 770.4114959000001,
"ma50": 767.5287948999999,
"name": "SPY",
"close": 769.65997,
"points": 1.4
},
"source": "twelvedata+fred"
}
},
"atrPct": 3.0337638039433106,
"atrPoints": 2,
"cciPoints": 0.8,
"vixPoints": 1.8,
"marketTrendPoints": 1.7999999999999998
}
},
"情緒分析": {
"max": 10,
"grade": "較差",
"items": {
"sentiment": {
"score": 4,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 4,
"negativeHits": 0,
"positiveHits": 1,
"sentimentScoreRaw": 0.6
}
},
"sentimentData": {
"raw": [
{
"id": 143205210,
"url": "https://finnhub.io/api/news?id=75ab2cb990a4fbedefee386c5c7a3d8ef379e14f75addf0dabc7fa52c3d45ecc",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "The past six months have been a windfall for Waters Corporation’s shareholders. The company’s stock price has jumped 51.7%, hitting $454.91 per share. This performance may have investors wondering how to approach the situation.",
"category": "company",
"datetime": 1793053367,
"headline": "2 Reasons to like WAT and 1 to stay skeptical"
},
{
"id": 143043366,
"url": "https://finnhub.io/api/news?id=99fa4d3e0bda26f1959fe16517cc76281572675f289f75fc28627765efbf6b56",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Waters Corporation has logged a powerful run in recent years, and the stock now sits at a level where investors naturally ask whether the current price is in line with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the question is how that cash flow based estimate stacks up against a share price that has already moved a long way. Over the past 3 years Waters has returned 77.7%, which puts real weight on getting the cash flow valuation call...",
"category": "company",
"datetime": 1792557067,
"headline": "Waters (WAT) Stock Looks 26% Overvalued On Cash Flow Estimates"
},
{
"id": 142730063,
"url": "https://finnhub.io/api/news?id=b4ec400d9af121f4582219f4a15c82ddddc99f351205421252b72488151aa5e5",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.",
"category": "company",
"datetime": 1791465000,
"headline": "Here's Why You Should Retain WAT Stock in Your Portfolio for Now"
},
{
"id": 142450773,
"url": "https://finnhub.io/api/news?id=e4f3fa1f1f92e08c17a14dfe916ac75d46bf808ad6edbd94d849eff1cb26fabd",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "In mid-September 2026, Everlywell announced a partnership with Waters Corporation to support at-home HPV cervical cancer screening, while Waters also launched the BD FACSDiscover A7 Cell Analyzer globally, expanding access to advanced flow cytometry for research labs. Together, these moves highlight Waters’ growing role in connected diagnostics and high-parameter cell analysis, deepening its presence across clinical and research workflows. Next, we’ll examine how the expanded at-home HPV...",
"category": "company",
"datetime": 1790550614,
"headline": "The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push"
}
],
"raw_source": [
{
"id": 143238397,
"url": "https://finnhub.io/api/news?id=123b58ad24fb079a3b83666a65de7d0245153a3ccc25616bf707bddfad20d273",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.",
"category": "company",
"datetime": 1793115060,
"headline": "Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests"
},
{
"id": 143205210,
"url": "https://finnhub.io/api/news?id=75ab2cb990a4fbedefee386c5c7a3d8ef379e14f75addf0dabc7fa52c3d45ecc",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "The past six months have been a windfall for Waters Corporation’s shareholders. The company’s stock price has jumped 51.7%, hitting $454.91 per share. This performance may have investors wondering how to approach the situation.",
"category": "company",
"datetime": 1793053367,
"headline": "2 Reasons to like WAT and 1 to stay skeptical"
},
{
"id": 143202820,
"url": "https://finnhub.io/api/news?id=dedac7e55ea3388ab12b0603e5f7af2043af8bf6cf9681e120f8b78c8a4ec212",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 31.5% over the past six months while the S&P 500 was up 6.8%.",
"category": "company",
"datetime": 1793039447,
"headline": "1 healthcare stock for long-term investors and 2 we ignore"
},
{
"id": 143201015,
"url": "https://finnhub.io/api/news?id=57e35b2bd284eb30a47293b8018e99be671d9e323f6d25cb064a537adbbe968a",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268513467/image_2268513467.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "WAT",
"summary": "The First Eagle U.S. Fund reported a 4.36% return for Q3 2026, outperforming the S&P 500. Read the full analysis for more details.",
"category": "company",
"datetime": 1793017800,
"headline": "First Eagle U.S. Value Fund Q3 2026 Portfolio Review"
},
{
"id": 143137585,
"url": "https://finnhub.io/api/news?id=1f7fc2368699870e1efc10f9dac10e71ba897dfb55efe711f4aac5b4ccafcac7",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening. The partnership focuses on at-home sample collection that can be processed through Quest Diagnostics laboratories using the Onclarity HPV assay. The two companies aim to widen access to clinically appropriate cervical cancer testing for patients who face barriers to in clinic screening. The Onclarity Self-Collection Kit...",
"category": "company",
"datetime": 1792797122,
"headline": "Quest Diagnostics (DGX) Backs At Home Cervical Cancer Screening"
},
{
"id": 143132441,
"url": "https://finnhub.io/api/news?id=9a6fb933e9b47bcf88a1bfbd04036b06b866bce5ba0cce7b0a846ec75f841f01",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026.",
"category": "company",
"datetime": 1792756800,
"headline": "Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026"
},
{
"id": 143134634,
"url": "https://finnhub.io/api/news?id=7e3bae8566dd0681484fe4ae49e9584b49998f9e0e75af3901b87b18ecc89c48",
"image": "",
"source": "Benzinga",
"related": "WAT",
"summary": "Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center,",
"category": "company",
"datetime": 1792742783,
"headline": "Waters And Labcorp To Expand Access To BD Onclarity HPV Assay"
},
{
"id": 143087262,
"url": "https://finnhub.io/api/news?id=eba9a293516889b9db11cf3881c5665bd9e741fb9e36f87cf455c1d1c54b430a",
"image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
"source": "ChartMill",
"related": "WAT",
"summary": "S&P 500 premarket movers on Oct. 21: SMCI, DELL, VRT, LITE, BE and HPE led gainers, while ISRG, NFLX, T, ABT and DHR led declines.",
"category": "company",
"datetime": 1792586166,
"headline": "S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines"
},
{
"id": 143043366,
"url": "https://finnhub.io/api/news?id=99fa4d3e0bda26f1959fe16517cc76281572675f289f75fc28627765efbf6b56",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Waters Corporation has logged a powerful run in recent years, and the stock now sits at a level where investors naturally ask whether the current price is in line with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the question is how that cash flow based estimate stacks up against a share price that has already moved a long way. Over the past 3 years Waters has returned 77.7%, which puts real weight on getting the cash flow valuation call...",
"category": "company",
"datetime": 1792557067,
"headline": "Waters (WAT) Stock Looks 26% Overvalued On Cash Flow Estimates"
},
{
"id": 143028934,
"url": "https://finnhub.io/api/news?id=42fb19fac55354e2499a0acbf2bc8308b27df6ce408c5e6156e04c9f73a7e9cc",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.",
"category": "company",
"datetime": 1792502400,
"headline": "Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows"
},
{
"id": 143029805,
"url": "https://finnhub.io/api/news?id=c270824aac8c817fd6f7f9381a53d4b6e8bb0a1c505153a9ab7ccc2ea7dd14ee",
"image": "https://image.cnbcfm.com/api/v1/image/108438094-17925143591792514357-49123421093-1080pnbcnews.jpg?v=1792514359&w=1920&h=1080",
"source": "CNBC",
"related": "WAT",
"summary": "Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's \"Halftime Report\" to spotlight Waters Corporation and Thermo Fisher in his \"Best Stocks in the Market.\"",
"category": "company",
"datetime": 1792500356,
"headline": "Josh Brown's \"Best Stocks in the Market:\" Waters and Thermo Fisher"
},
{
"id": 143023828,
"url": "https://finnhub.io/api/news?id=f54cdd1ff502cc03ae8cc6fa900a19470b9424c6f9b04dad5cc253b2ff8355f1",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a collaboration intended to broaden access to clinically appropriate at-home cervical cancer screening through the FDA-cleared Onclarity™ Self-Collection Kit.1,2,13",
"category": "company",
"datetime": 1792497600,
"headline": "Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option"
},
{
"id": 143010668,
"url": "https://finnhub.io/api/news?id=9682767f5944a8ea16d51193bbbb60c91179082a7ddd93cf47f710e54a272e0e",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Waters Corporation is all geared up to release its third-quarter earnings next month, and analysts anticipate a double-digit boost in its profitability.",
"category": "company",
"datetime": 1792416569,
"headline": "Earnings Preview: What to Expect From Waters Corporation’s Report"
},
{
"id": 142997770,
"url": "https://finnhub.io/api/news?id=ab33f6812a39173b4bbf8ed1420620525807eec66531b4c62963c1ee560e41ed",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "LONDON, October 19, 2026--IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company using its High Definition Immunology™ platform to better understand the immune system and drive a shift in how we understand, diagnose, and treat disease, has today announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood samples collected from UK Biobank participants.",
"category": "company",
"datetime": 1792393680,
"headline": "IMU and UK Biobank to generate the world’s most detailed, large-scale picture of the human immune system for advancing research into health and disease"
},
{
"id": 142997771,
"url": "https://finnhub.io/api/news?id=808170f23fc379497c6b8a60ecfb66493710c5f63b2904675d23968f8632c6b4",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Ultima Genomics, Inc., developer of ultra-high-throughput next-generation sequencing (NGS) platforms, today announced that its recently launched UG200 Sequencing Platform has been selected to power a new large-scale immune profiling study with IMU Biosciences and UK Biobank. The study will generate one of the most detailed pictures of the human immune system assembled to date, adding a high-resolution immune data layer and a foundational dataset for AI to UK Biobank, one of the world's most impo",
"category": "company",
"datetime": 1792393500,
"headline": "Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation"
},
{
"id": 142945309,
"url": "https://finnhub.io/api/news?id=5040160360ff4c52ef340a2bb9f579c9f01e9f273c2f8bb5c296d5105ee48fa6",
"image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "WAT",
"summary": "Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.71% on an annualized basis producing an average annual return of 11.7%. Currently, Waters has a market capitalization of $42.17 billion. \nBuying",
"category": "company",
"datetime": 1792082731,
"headline": "Here’s How Much You Would Have Made Owning Waters Stock In The Last 20 Years"
},
{
"id": 142966507,
"url": "https://finnhub.io/api/news?id=2d2d13366651733cb1b6145af866a2a92742630d55dba52d18f49e1906822cb7",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.",
"category": "company",
"datetime": 1791892800,
"headline": "Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release"
},
{
"id": 142883797,
"url": "https://finnhub.io/api/news?id=c3d7953d6a5d896f03542e49db2c603dc931f592f1870598f157171386a6fa0b",
"image": "",
"source": "Benzinga",
"related": "WAT",
"summary": "TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Buy and raises the price target from $475 to $515.",
"category": "company",
"datetime": 1791892541,
"headline": "TD Cowen Maintains Buy on Waters, Raises Price Target to $515"
},
{
"id": 142730063,
"url": "https://finnhub.io/api/news?id=b4ec400d9af121f4582219f4a15c82ddddc99f351205421252b72488151aa5e5",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.",
"category": "company",
"datetime": 1791465000,
"headline": "Here's Why You Should Retain WAT Stock in Your Portfolio for Now"
},
{
"id": 142728490,
"url": "https://finnhub.io/api/news?id=6c2f069d7813e573b0ce8d7ac211fac811097d76de78e6fe7f5c54ae9933a351",
"image": "",
"source": "Benzinga",
"related": "WAT",
"summary": "Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $460 to $500.",
"category": "company",
"datetime": 1791373046,
"headline": "Barclays Maintains Overweight on Waters, Raises Price Target to $500"
},
{
"id": 142695692,
"url": "https://finnhub.io/api/news?id=85c2474c0ddb084841e4c085e22b2a859b346cac22eac3c0e8722cd9d7ee988a",
"image": "https://cdn.benzinga.com/files/images/story/2026/10/07/SP-500-Set-To-Surge-Like-Never-Before-Be.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "WAT",
"summary": "Micron, Sandisk and Nvidia lead seven S&P 500 stocks that more than doubled quarterly revenue. Six sell AI hardware.",
"category": "company",
"datetime": 1791367570,
"headline": "Nvidia, Micron and Other 5 S&P 500 Stocks With +100% Revenue Growth"
},
{
"id": 142694485,
"url": "https://finnhub.io/api/news?id=205ddd44ff6f1452e358342025e56e33cb0dfa365f5e2fbc16991e2a8a53e86d",
"image": "https://cdn.benzinga.com/files/images/story/2026/10/06/Golden-Bull-Figurine-In-Foreground-With-.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "WAT",
"summary": "The S&P 500 hit a record high Tuesday, but only 15 of its 504 stocks did too. The median member trades 25% below its own peak.",
"category": "company",
"datetime": 1791300578,
"headline": "The S&P 500 Is Partying at Record Highs: Only 3% of Its Stocks Were Invited"
},
{
"id": 142662145,
"url": "https://finnhub.io/api/news?id=39eb1cdfec2b24808a3835bbdbb63f47c6b13870f9b4d20c113dec5d245a3d8e",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Under the framework, the two organisations will initially focus on flow cytometry-based programmes.",
"category": "company",
"datetime": 1791282532,
"headline": "CellCarta, Waters Corporation collaborate on companion diagnostics"
},
{
"id": 142635380,
"url": "https://finnhub.io/api/news?id=628d8c80b6c2955b506f4753f539d2fb80521c012b22fa288d5d3c6b9ca77bc3",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic partnership with Waters Corporation, a global leader in life sciences and diagnostics, creating a framework to jointly pursue companion diagnostic (CDx) and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies.",
"category": "company",
"datetime": 1791206100,
"headline": "CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development"
},
{
"id": 142633835,
"url": "https://finnhub.io/api/news?id=2eb8408fc2372f0d7df88dbbc9133e3a1155d872cc69ffa7774a7678864fa389",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2276411485/image_2276411485.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "WAT",
"summary": "First Trust Water ETF keeps underperforming the broader market, implying that there's more to consider than just demand. I rate the FIW ETF as Sell. Click to read my analysis.",
"category": "company",
"datetime": 1791185457,
"headline": "FIW: Massive Water Infrastructure Needs Aren't Enough To Justify A Buy"
},
{
"id": 142557975,
"url": "https://finnhub.io/api/news?id=7c585765141d5585e6d79175cfa3839c39250530199bd4ad81048f0ffa47e24e",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 1, 2026, at midnight Eastern Time.",
"category": "company",
"datetime": 1790859600,
"headline": "Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call"
},
{
"id": 142559165,
"url": "https://finnhub.io/api/news?id=a369a81d6c981559e667e1d316ee895227cc3414ab79c9d2d8a1f5fca1c4fcd3",
"image": "",
"source": "Benzinga",
"related": "WAT",
"summary": "Guggenheim analyst Subbu Nambi maintains Waters (NYSE:WAT) with a Buy and raises the price target from $440 to $490.",
"category": "company",
"datetime": 1790848043,
"headline": "Guggenheim Maintains Buy on Waters, Raises Price Target to $490"
},
{
"id": 142559166,
"url": "https://finnhub.io/api/news?id=54a96966f4bee0ee2424358170e80a4b6330876c9576d750f0ffe11ba9fb481c",
"image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "WAT",
"summary": "Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.95% on an annualized basis producing an average annual return of 11.99%. Currently, Waters has a market capitalization of $43.33 billion. \nBuying",
"category": "company",
"datetime": 1790795749,
"headline": "If You Invested $1000 In Waters Stock 20 Years Ago, You Would Have This Much Today"
},
{
"id": 142513513,
"url": "https://finnhub.io/api/news?id=4ce869aadf41f489c7b7dafd967ff0fd20e41fe2914cacf122b79c047b5490c9",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.",
"category": "company",
"datetime": 1790762713,
"headline": "1 Volatile Stock with Promising Prospects and 2 We Avoid"
},
{
"id": 142450773,
"url": "https://finnhub.io/api/news?id=e4f3fa1f1f92e08c17a14dfe916ac75d46bf808ad6edbd94d849eff1cb26fabd",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "WAT",
"summary": "In mid-September 2026, Everlywell announced a partnership with Waters Corporation to support at-home HPV cervical cancer screening, while Waters also launched the BD FACSDiscover A7 Cell Analyzer globally, expanding access to advanced flow cytometry for research labs. Together, these moves highlight Waters’ growing role in connected diagnostics and high-parameter cell analysis, deepening its presence across clinical and research workflows. Next, we’ll examine how the expanded at-home HPV...",
"category": "company",
"datetime": 1790550614,
"headline": "The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push"
}
],
"data_source": "finnhub_news_keyword_model",
"article_count": 4,
"negative_hits": 0,
"positive_hits": 1,
"recomputed_at_score": true,
"sentiment_score_raw": 0.6,
"source_article_count": 30,
"discarded_article_count": 26
},
"sentimentPoints": 4
}
},
"技術信號": {
"max": 30,
"raw": 20.9,
"grade": "一般",
"items": {
"bbPoints": 3,
"adxPoints": 3,
"sarPoints": 2.4000000000000004,
"vcpPoints": 1.4,
"macdPoints": 4,
"vcpPayload": {
"vcp_pass": false,
"vcp_score": 1.4,
"vcp_reason": "站上MA50；升放量(近10日4日)；收盤突破20日高位；Ready=N；Confirm=Y",
"vcp_metrics": {
"up_days": 5,
"vol_ref": 863680,
"down_days": 4,
"vcp_ready": false,
"above_ma50": true,
"avg_vol_10": 916110,
"avg_vol_20": 890045,
"avg_vol_30": 863680,
"range_pct_10": 0.09076939687908216,
"range_pct_20": 0.0933731745464342,
"range_pct_30": 0.11411798344078497,
"up_expand_ok": true,
"lookback_used": 59,
"near_20d_high": true,
"contraction_ok": false,
"down_shrink_ok": false,
"up_expand_days": 4,
"breakout_20d_ok": true,
"vol_ratio_10_30": 1.0607053538347535,
"dist_to_20d_high": -0.006854908175496561,
"down_shrink_days": 1,
"breakout_level_20d": 465.35999,
"vcp_breakout_confirm": true,
"contraction_ratio_10_30": 0.7953995868335841
},
"vcp_name_en": "Volatility Contraction Pattern",
"vcp_name_zh": "波動收縮形態",
"vol_contraction": false
},
"kdjAdxPoints": 0.7,
"rsiKdjPoints": 3.2,
"volumeWeight": 2,
"maCrossPoints": 1.6,
"shortRsiPoints": 0.4,
"shortMacdPoints": 0.4,
"volConfirmPoints": 0,
"volumePointsTechnical": 0.8
}
},
"風險管理": {
"max": 10,
"grade": "一般",
"items": {
"position": {
"score": 1.3,
"details": {
"atrPct": 3.0337638039433106,
"turnoverUsdM": 373.59130627665,
"liquidityPoints": 0.6,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.6,
"stopLevels": {
"symbol": "US.WAT",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 440.1206,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 3,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1.5,
"stop_loss_percent": 6.1,
"take_profit_price": 510.2464,
"target_multiplier": 2.2,
"technical_strength": 2,
"take_profit_percent": 8.9
},
"positionPoints": 1.3,
"stopLossPoints": 1.8,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.4668248049554333,
"stopLossPercent": 6.067527607886621,
"diversificationPoints": 2
}
}
}
},
"modelVersion": "cursor_18_27_news_v2_160",
"providerErrors": [],
"rankingScoreMax": 160,
"dataCompleteness": {
"complete": true,
"missingFields": [],
"optionalInputs": [
"institutionalData"
],
"requiredInputs": [
"fundamentals",
"marketContext.VIX",
"marketContext.SPY",
"marketContext.QQQ",
"catalystData",
"sentimentData",
"ATR",
"sector"
],
"optionalInputWarnings": []
},
"technicalIndicators": {
"adx": 92.86,
"atr": {
"atr": 14.2147,
"rule": "ATR / current price; lower volatility scores higher",
"score": 4,
"atr_pct": 3.03
},
"cci": {
"rule": "Cursor_18.24 CCI bands",
"level": "超買或超賣風險",
"score": 2,
"value": 187.52
},
"cmf": {
"rule": "Cursor_18.24 CMF bands",
"level": "平衡",
"score": 4,
"value": 0.0579
},
"kdj": {
"d": 71.73,
"j": 97.23,
"k": 80.23,
"rule": "Cursor_18.24 K/D cross",
"score": 4,
"signal": "金叉"
},
"mfi": {
"rule": "Cursor_18.24 MFI bands",
"level": "平衡",
"score": 6,
"value": 59.95
},
"obv": {
"rule": "Cursor_18.24 recent_slope vs previous_slope",
"score": 10,
"trend": "強流入",
"value": 5336835,
"recentSlope": 89803.5,
"previousSlope": -325970
},
"rsi": 69.65,
"sar": {
"rule": "Cursor_18.24 Parabolic SAR",
"score": 8,
"trend": "上升",
"value": 431.988,
"position": "SAR喺價下",
"distancePct": 7.8,
"previousTrend": "上升"
},
"ma50": 426.2274,
"macd": {
"macd": 9.320561685344273,
"trend": "強烈看漲",
"signal": 7.10288491334309,
"histogram": 2.217676772001184
},
"vwap": {
"rule": "Cursor_18.24 VWAP 20D consecutive close",
"score": 10,
"value": 440.5471,
"position": "連續5日>VWAP",
"consecutiveAbove": 10
},
"volume": {
"rule": "Cursor_18.24 volume ratio",
"level": "無力",
"ratio": 0.89,
"score": 4,
"avgVolume": 898632,
"currentVolume": 797335
},
"derived": {
"ma20": 440.6455,
"ma50": 426.2274,
"prevClose": 455.98,
"avgVolume10": 889164,
"avgVolume20": 898632,
"changePercent": 2.76,
"avgVolumeForScore": 898632
},
"ma_cross": {
"ma20": 440.6455,
"ma50": 426.2274,
"rule": "Cursor_18.24 MA20/MA50 cross",
"cross": "多頭",
"score": 4,
"prevMa20": 439.381,
"prevMa50": 425.0112,
"spreadPct": 3.38,
"isVolumeBreakout": false
},
"bollinger": {
"lower": 417.5366,
"upper": 463.7544,
"position": "上半部"
},
"rsi_short": 90.93,
"macd_short": {
"macd": 0,
"trend": "中性",
"signal": 0,
"histogram": 0
},
"volume_ratio": {
"ratio": 0.89
}
}
}
Raw metrics JSON
{
"close": 468.55,
"volume": 797335,
"changePercent": 2.76
}
Scores are derived from cached daily market data using the Solorank 110-point standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.